ORPHA:178528
Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma
Also known as: Berti lymphoma · Primary cutaneous epidermotropic cytotoxic CD8+ T-cell lymphoma
Publications
47
37.8th percentile
Trials
0
Interventional, condition-specific
Researchers
229
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma is a rare form of primary cutaneous T-cell lymphoma characterized by rapidly progressing, localized or disseminated nodules, tumors or eczematous skin lesions. It has a particularly aggressive clinical course with a high tendency to spread, in advanced stages, to extracutaneous locations (the central nervous system, lung, testes). Lymph nodes are often spared.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015811
- UMLS:C4518232
- NCIT:C45339
Additional Mondo synonyms (1)
primary cutaneous epidermotropic cytotoxic CD8+ T-cell lymphoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
47 matched papers (21 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
47
47 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
47 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
21 in the last 10 years · high confidence · 37.8th percentile (publications denominator)
Phrase hits: 47 · MeSH hits: 0
Who's working on it?
229
Distinct author names in 47 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Abdel-Mawla MY2 papers · 2014Papers in Europe PMC
- 02Assaf M2 papers · 2014Papers in Europe PMC
- 03Cerroni L2 papers · 2019
Department of Dermatology, Medical University of Graz, Austria. lorenzo.cerroni@meduni-graz.at
Papers in Europe PMC - 04Csomor J2 papers · 2016
1st Department of Pathology and Experimental Cancer Research Institute, Semmelweis University, Budapest, Hungary.
Papers in Europe PMC - 05Gaulard P2 papers · 2015
Département de Pathologie, Hôpital Henri Mondor, Université paris Est, Créteil, France.
Papers in Europe PMC - 06Jaffe ES2 papers · 2019
Hematopathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Papers in Europe PMC - 07Magro C2 papers · 2025
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College New York City, New York, 10065.
Papers in Europe PMC - 08Marschalkó M2 papers · 2016
Department of Dermatology Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary.
Papers in Europe PMC - 09Matolcsy A2 papers · 2016
1st Department of Pathology and Experimental Cancer Research Institute, Semmelweis University, Budapest, Hungary.
Papers in Europe PMC - 10Nofal A2 papers · 2014
Department of Dermatology, Faculty of Medicine, Zagazig University, Zagazig, Egypt. ahmadnofal5@hotmail.com
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma" OR "Berti lymphoma" OR "Primary cutaneous epidermotropic cytotoxic CD8+ T-cell lymphoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma" OR "Berti lymphoma" OR "Primary cutaneous epidermotropic cytotoxic CD8+ T-cell lymphoma"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T08:54:37.518Z